---
title: "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298654242.md"
description: "Pomerantz LLP is investigating potential securities fraud by Tyra Biosciences (NASDAQ: TYRA) and its officers. The probe follows a September 9, 2026 press release regarding SURF302 study results, which cited adverse events in some participants. Consequently, Tyra's stock dropped 17.66% to $22.01. Investors are advised to contact the firm if they wish to join the class action."
datetime: "2026-09-10T23:20:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298654242.md)
  - [en](https://longbridge.com/en/news/298654242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298654242.md)
generator: "portal-rs"
---

# INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at \[email protected\] or 646-581-9980, ext. 7980.

The investigation concerns whether Tyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

**\[Click here for information about joining the class action\]**

On September 9, 2026, Tyra issued a press release "announc\[ing\] initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)." While the Company said that the data indicated a favorable safety profile, 14% and 9% of participants in the 60 mg once-daily ("QD") and 50 mg QD dose cohorts experienced Grade 3 treatment-emergent adverse events. 

On this news, Tyra's stock price fell $4.72 per share, or 17.66%, to close at $22.01 per share on September 9, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**  
Danielle Peyton  
Pomerantz LLP  
\[email protected\]  
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)

## Related News & Research

- [Tyra Biosciences to Participate in Upcoming Investor Conferences](https://longbridge.com/en/news/304524410.md)
- [TYRA: Dabogratinib advances across three FGFR3 indications, led by IR NMIBC activity](https://longbridge.com/en/news/305035696.md)
- [Tyra Biosciences Q3 net loss widens on higher R&D costs](https://longbridge.com/en/news/305016712.md)
- [Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary](https://longbridge.com/en/news/305019126.md)
- [Tyra Biosciences (TYRA) Set to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/303386581.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**